A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome

BACKGROUND: Primary Sjögren’s syndrome (pSS) is characterized by B cell hyperactivity and elevated B-lymphocyte stimulator (BLyS). Anti-BLyS treatment (e.g., belimumab) increases peripheral memory B cells; decreases naive, activated, and plasma B cell subsets; and increases stringency on B cell sele...

Descripción completa

Detalles Bibliográficos
Autores principales: Mariette, Xavier, Barone, Francesca, Baldini, Chiara, Bootsma, Hendrika, Clark, Kenneth L., De Vita, Salvatore, Gardner, David H., Henderson, Robert B., Herdman, Michael, Lerang, Karoline, Mistry, Prafull, Punwaney, Raj, Seror, Raphaele, Stone, John, van Daele, Paul L.A., van Maurik, André, Wisniacki, Nicolas, Roth, David A., Tak, Paul Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746921/
https://www.ncbi.nlm.nih.gov/pubmed/36477362
http://dx.doi.org/10.1172/jci.insight.163030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746921/
https://www.ncbi.nlm.nih.gov/pubmed/36477362
http://dx.doi.org/10.1172/jci.insight.163030

Ejemplares similares